Drug Discovery & Pharmaceuticals

RSS

NVIDIA Announces BioNeMo Agent Toolkit — Tools for Agents to Accelerate Scientific Discovery

NVIDIA today announced NVIDIA BioNeMo Agent Toolkit, which provides domain-specific tools and skills for the agentic life sciences era.

From Benchling 25 Jun 2026

Penn Study Uses AI to Discover Prion-Based Antibiotics

New antibiotic candidates for drug-resistant bacteria may reside inside prions, mis-folded protein in the brain best known for rare and fatal degenerative brain diseases.

22 Jun 2026

Streamlining Complex Drug Development by Directly Editing Core Molecular Frameworks

For more than a hundred years, chemists have been building complex molecules step by step – bond by bond, atom by atom.

16 Jun 2026

AI Decodes Biomolecular Condensates to Revolutionize Drug Discovery

Researchers at Princeton University have harnessed AI to understand how drugs affect the dynamics of vital structures within the cell.

13 Jun 2026

Cryo-EM Study Unlocks Structural Secrets of RNA Therapeutics

RNA therapeutics have emerged as one of the most promising new classes of medicines. Eight small interfering RNA (siRNA) drugs have already been approved worldwide for the treatment of genetic diseases, yet scientists have not fully understood one of the most fundamental steps underlying their function: how Argonaute, the core protein responsible for gene silencing, becomes activated.

11 Jun 2026

DNA Barcode Technology Enables Massive Simultaneous Drug Candidate Validation

A Korean research team has launched a public drug discovery service capable of screening and validating tens of millions of compounds simultaneously.

10 Jun 2026

UIC Scientists Discover Antibiotic to Fight Drug-Resistant Superbugs

Scientists at the University of Illinois Chicago have discovered a new antibiotic that may be a bulwark in the fight against drug-resistant superbugs, according to new research published in Nature.

10 Jun 2026

Drug Boosts Axon Regrowth In Human Brain-Spinal Cord Model

This study presents a human organoid model that identifies genetic factors limiting nerve regeneration and highlights lynestrenol's role in promoting repair.

4 Jun 2026

Webinar - Modality Agnostic Drug Discovery Strategies for Data Sparse Targets: Lessons Learned From Avammune & Cresset, Hosted by Visioneers

Are you working on data-sparse or novel targets? Join us June 11th to learn how Avammune progressed from early concepts to trial-stage candidates in this space.

From Cresset 4 Jun 2026

Bispecific Antibodies Target Tumors While Sparing Healthy Tissue

A new generation of bispecific antibodies effectively targets cancer cells, minimizing toxicity and enhancing treatment precision in preclinical studies.

3 Jun 2026

Introducing Evosep Proteomics to Standardize and Scale Proteomics for Research and Drug Development

Evosep announces the launch of Evosep Proteomics, an ecosystem designed to standardize and scale LC-MS-based proteomics for research and pharmaceutical drug development.

From Evosep 2 Jun 2026

Redesigning Antibiotics to Overcome Bacterial Efflux Pump Resistance

A new way of designing antibiotics could support the discovery of new treatments for drug-resistant infections.

1 Jun 2026

Nanoparticles Boost Delivery of Lung Cancer Drugs 30-Fold

Lung cancer remains one of the world’s deadliest cancers, yet despite decades of effort to develop new drugs, many fail because they don’t stay in the body long enough to be effective or because they damage healthy organs.

1 Jun 2026

MRM Health Rewarded a € 2.6 M VLAIO Research Grant to Accelerate the Development of Novel Therapeutics that Redefine the Treatment of Immune-Mediated Inflammatory Diseases

MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that it has been awarded a research grant of € 2.6M from Flanders Innovation and Entrepreneurship (VLAIO), a government organization with the goal to stimulate economic development in Flanders, Belgium.

29 May 2026

New TriPcide Antibiotics Kill Dormant MRSA Without Resistance

The study on TriPcides reveals their ability to combat MRSA and dormant bacteria, offering a new strategy to address antimicrobial resistance in public health.

27 May 2026

Scientists Synthesize Rare Sea Sponge Molecules to Boost Future Cancer Drug Development

Florida State University chemists have synthesized new molecules derived from bacteria found in a Pacific Ocean sea sponge, a breakthrough for the future of drug development, particularly for rare forms of cancer.

21 May 2026

New 3D Cortical Tissue Models Incorporate Microglia to Bridge Preclinical Translation Gaps

28bio today announced CNS-3D Inflammatory Organoids, designed to evaluate efficacy of anti-inflammatory drugs by quantifying their ability to reduce inflammatory injury, preserve tissue health, and restore neuronal network activity.

20 May 2026

New 3D Human Liver Model Mimics Chronic Disease For 30 Days

Researchers developed a 3D liver model that functions for a month, replicating inflammation and fibrosis, crucial for studying liver diseases and therapies.

19 May 2026

Novel Formicitoxins Found in Carpenter Ant Venom Offer Drug Discovery Impetus

The venom of forest ants and horse ants contains numerous substances that protect the insects from pathogens. Researchers at Martin Luther University Halle-Wittenberg (MLU) and Freie Universität Berlin have succeeded for the first time in identifying and characterizing these novel antimicrobial substances in the insects' venom.

19 May 2026

Restricted Interaction Peptides Change Shape to Lock Therapy Inside Solid Tumors

Medications are designed to treat diseased tissues while sparing healthy ones, often by attaching the drug to something that helps guide it directly to its target.

14 May 2026